Special Issue "Host Targeted Therapeutics against Virus Infections"

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: 31 May 2022.

Special Issue Editors

Prof. Dr. Oliver Planz
E-Mail Website
Guest Editor
Eberhard Karls University, Tuebingen, Germany
Interests: immunology of viral infections; host cell targeted antivirals; virus cell interaction
Prof. Dr. Stephan Ludwig
E-Mail Website
Guest Editor
Westfälische Wilhelms University, Muenster, Germany
Interests: host cell signaling in inflammation and infection; cell signaling targeted antivirals
Prof. Dr. Stephan Pleschka
E-Mail Website
Guest Editor
Justus Liebig University, Giessen, Germany
Interests: molecular biology/genetics of IV; viral factors allowing host infection; cellular functions essential for IV replication
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

The current Covid-19 pandemic and the frequent emergence and re-emergence of novel viruses highlights the urgent need for effective antivirals. The fact that every virus needs host cells to replicate sparked increasing interest in host-directed drugs that act as antivirals (host-targeted antivirals, HTA). While this approach had been heavily debated 20 years ago, the idea to target host functions for antiviral therapy was boosted due to technical developments such as cell-omics approaches and has now become widely accepted. (inhibitors of cell signaling pathways have received special attention in this respect). In this Special Issue, we want to summarize the latest findings in this field and would like to encourage research groups working on host-targeted antivirals to submit their latest findings.

Prof. Dr. Oliver Planz
Prof. Dr. Stephan Ludwig
Prof. Dr. Stephan Pleschka
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • influenza
  • COVID-19
  • host targeting antivirals
  • inhibitors of post translational modification and maturation of viral proteins
  • inhibitors of viral entry and intra-cellular transport

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Multi-Tissue Transcriptomic-Informed In Silico Investigation of Drugs for the Treatment of Dengue Fever Disease
Viruses 2021, 13(8), 1540; https://doi.org/10.3390/v13081540 - 04 Aug 2021
Viewed by 324
Abstract
Transcriptomics, proteomics and pathogen-host interactomics data are being explored for the in silico–informed selection of drugs, prior to their functional evaluation. The effectiveness of this kind of strategy has been put to the test in the current COVID-19 pandemic, and it has been [...] Read more.
Transcriptomics, proteomics and pathogen-host interactomics data are being explored for the in silico–informed selection of drugs, prior to their functional evaluation. The effectiveness of this kind of strategy has been put to the test in the current COVID-19 pandemic, and it has been paying off, leading to a few drugs being rapidly repurposed as treatment against SARS-CoV-2 infection. Several neglected tropical diseases, for which treatment remains unavailable, would benefit from informed in silico investigations of drugs, as performed in this work for Dengue fever disease. We analyzed transcriptomic data in the key tissues of liver, spleen and blood profiles and verified that despite transcriptomic differences due to tissue specialization, the common mechanisms of action, “Adrenergic receptor antagonist”, “ATPase inhibitor”, “NF-kB pathway inhibitor” and “Serotonin receptor antagonist”, were identified as druggable (e.g., oxprenolol, digoxin, auranofin and palonosetron, respectively) to oppose the effects of severe Dengue infection in these tissues. These are good candidates for future functional evaluation and clinical trials. Full article
(This article belongs to the Special Issue Host Targeted Therapeutics against Virus Infections)
Show Figures

Figure 1

Back to TopTop